系统综述与荟萃分析:肝移植为慢加急性肝衰竭患者提供生存获益
该系统综述与荟萃分析汇总12项研究数据,比较慢加急性肝衰竭(ACLF)患者接受肝移植与未接受移植的ACLF患者或非ACLF移植受者的结局。结果显示ACLF患者移植后各时间点生存率均低于非ACLF受者,但显著高于未移植的ACLF患者;ACLF-3患者结局更差,ACLF-1和ACLF-2较好。作者认为肝移植为部分ACLF患者提供生存获益,但需更大规模前瞻性研究完善选择标准。
要点
- ACLF患者肝移植后30天、90天、6个月、1年、5年生存率均低于非ACLF移植受者(P<0.01)。
- ACLF患者接受肝移植后30天和1年生存率显著高于未选择移植的ACLF患者(P<0.001)。
- 移植时ACLF-3患者结局更差,ACLF-1和ACLF-2患者结局较好。
核心结论
- 在这项全球范围大样本的汇总分析中,为经过选择的ACLF患者进行肝移植提供了生存获益。
- 需要更大规模的前瞻性研究来进一步完善选择标准,尤其是ACLF-3患者,以改善结局并优化稀缺供体库的利用。
研究设计与样本
- 系统综述与荟萃分析,汇总12项关于ACLF患者肝移植结局的研究数据。
- 其中9项研究比较ACLF移植受者(22 238例)与非ACLF移植受者(30 791例)。
- 其中3项研究比较ACLF移植受者(441例)与未选择肝移植的ACLF患者(301例)。
主要发现
- ACLF移植受者较非ACLF移植受者年轻1.1岁,男性比例较低(64% vs 66.4%),终末期肝病模型评分高14.5(14.4-14.6),所有P<0.01。
- ACLF患者移植后30天、90天、6个月、1年、5年患者生存率分别为96.2% vs 98.1%、92.6% vs 96.2%、89.9% vs 94.4%、86.0% vs 91.9%、66.9% vs 80.7%,均低于非ACLF受者,所有P<0.01。
- ACLF患者住院时间和ICU时间分别延长5.7天和10.5天,P<0.001;移植后并发症发生率相似(74.4% vs 55.5%,P=0.12)。
- ACLF移植受者较未选择肝移植的ACLF患者30天和1年生存率更高:95.2% vs 60%和85.3% vs 28.2%,P<0.001。
- 移植时ACLF-3患者结局更差,ACLF-1和ACLF-2患者结局较好。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更大规模的前瞻性研究来进一步完善选择标准,尤其是ACLF-3患者,以改善结局并优化稀缺供体库的利用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on liver transplantation (LT) in acute on chronic liver failure (ACLF) are scanty. AIM: To perform meta-analysis on outcomes after LT for ACLF compared with ACLF patients not receiving LT or with LT recipients for indications other than ACLF. METHODS: We pooled data from 12 studies on LT outcomes among ACLF patients. RESULTS: Among nine studies, 22 238 LT recipients for ACLF vs 30 791 for non-ACLF were younger by 1.1 years, less males (64% vs 66.4%), and higher model for end-stage disease score by 14.5 (14.4-14.6), P < 0.01 for all. Post-transplant patient survival at 30 day, 90 day, 6 months, 1 year and 5 years was lower in ACLF: 96.2% vs 98.1%, 92.6% vs 96.2%, 89.9% vs 94.4%, 86.0% vs 91.9%, 66.9% vs 80.7% respectively, P < 0.01 for all. ACLF patients stayed longer in hospital and ICU by 5.7 and 10.5 days respectively, P < 0.001, with similar post-transplant complications [74.4% vs 55.5%, P = 0.12]. Among three studies, 441 LT recipients for ACLF vs 301 ACLF patients not selected for LT had better 30 day and 1 year survival: 95.2% vs 60% and 85.3% vs 28.2% respectively, P < 0.001. Outcomes were worse in ACLF-3 and better for ACLF-1 and ACLF-2 patients at the time of LT. CONCLUSION: In this pooled analysis with a large sample size across the globe, LT for select patients with ACLF provided survival benefit. However, larger prospective studies are needed to further refine selection criteria, especially for ACLF-3 patients as basis for improving outcomes and optimal utilisation of scarce donor pool.
引用
- Abdallah MA, Waleed M, Bell MG, et al. Systematic review with meta-analysis: liver transplant provides survival benefit in patients with acute on chronic liver failure. Aliment Pharmacol Ther. 2020. PMID: 32490550. doi:10.1111/apt.15793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。